Global Cytomegalovirus Infection Treatment Market By Drug Class (Antiviral drugs, Foscarnet, Cytovene, Vistide, Others), By Infection (Retinitis, Pneumonia, Gastroenteritis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography 

 

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Cytomegalovirus Infection Treatment Market size is valued at USD 278.65 million in 2021 and is expected to reach USD 288.18 million by 2028, at a CAGR of 4.85% during the forecast period 2022-2028. Cytomegalovirus (CMV) infection is the common herpes virus infection having different symptoms which occurs in all ages of people around the world. Cytomegalovirus (CMV) infection is a communicable and easily prone through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and Blood transfusion are the other way for the transmission of the disease. Cytomegalovirus infection treatment market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, pipeline drugs which are promising by key market players for the treatment of CMV infection. Moreover, rise in the support of government, and development of healthcare infrastructure are anticipated to fuel the growth of CMV infection treatment market. However, recent expiries of patented drugs, generic drugs that are available for the treatment like Ganciclovir & Foscarnet are anticipated to hamper the market growth of cytomegalovirus infection treatment.  this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Cytomegalovirus Infection Treatment Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Cytomegalovirus Infection Treatment Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Global Cytomegalovirus Infection Treatment Market Summary

Study Period

2023-29

Base Year

2022

CAGR

4.85%

Largest Market

North-America

Fastest Growing Market

Europe
Cytomegalovirus Infection Treatment Market Dynamics

The cytomegalovirus treatment industry is predicted to increase substantially as the number of cases with CMV retinitis rises. CMV retinitis is a rather uncommon symptom of viral disease in other vulnerable groups. It is the earliest symptom of CMV infection in persons with AIDS. In up to 25% of AIDS patients, cytomegalovirus retinitis occurs. A symptom of CMV retinitis is necrotizing retinitis, which can cause retinal organisation and blindness. CMV retinitis and other cytomegalovirus disease symptoms in HIV-1 patients are opportunistic infections that happen when CD4+ cell counts are extremely low. High-value-added active antiretroviral therapy will drive the market for CMV treatment. The global cytomegalovirus treatment market is being driven by the increased demand for CMV therapy due to the rising prevalence of cytomegalovirus retinitis in AIDS patients.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Cytomegalovirus Infection Treatment Market Segmentation

By Drug Class
  • Antiviral drugs
    • Foscarnet
    • Cytovene
    • Vistide
    • Others
By Infection
  • Retinitis
  • Pneumonia
  • Gastroenteritis
  • Others (Mouth Ulcers, Pharyngitis, etc.)
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

1. Executive Summary 2. Global Cytomegalovirus Infection Treatment Market Introduction 2.1. Global Cytomegalovirus Infection Treatment Market – Taxonomy 2.2. Global Cytomegalovirus Infection Treatment Market –Definitions 2.2.1. Drug Type 2.2.2. Distribution Channel 3. Global Cytomegalovirus Infection Treatment Market Dynamics 3.1. Drivers 3.2. Restraints 3.3. Opportunities/Unmet Needs of the Market 3.4. Trends 3.5. Global Cytomegalovirus Infection Treatment Market Dynamic Factors - Impact Analysis 4. Global Cytomegalovirus Infection Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 4.3. Market Opportunity Analysis 5. Global Cytomegalovirus Infection Treatment Market, By Drug Type, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.1. Foscarnet 5.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.1.3. Market Opportunity Analysis 5.2. Cytovene 5.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.2.3. Market Opportunity Analysis 5.3. Vistide 5.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.3.3. Market Opportunity Analysis 5.4. Others 5.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.4.3. Market Opportunity Analysis 6. Global Cytomegalovirus Infection Treatment Market, By Infection, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.1. Retinitis 6.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.1.3. Market Opportunity Analysis 6.2. Pneumonia 6.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.2.3. Market Opportunity Analysis 6.3. Gastroenteritis 6.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.3.3. Market Opportunity Analysis 6.4. Others (Mouth Ulcers, Pharyngitis, etc.) 6.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.4.3. Market Opportunity Analysis 7. Global Cytomegalovirus Infection Treatment Market, By Distribution Channel, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.1. Hospital Pharmacies 7.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.1.3. Market Opportunity Analysis 7.2. Retail Pharmacies 7.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.2.3. Market Opportunity Analysis 7.3. Online Pharmacies 7.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.3.3. Market Opportunity Analysis 8. Global Cytomegalovirus Infection Treatment Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.1. North America 8.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.1.3. Market Opportunity Analysis 8.2. Europe 8.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.2.3. Market Opportunity Analysis 8.3. Asia-Pacific 8.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.3.3. Market Opportunity Analysis 8.4. Latin America 8.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.4.3. Market Opportunity Analysis 8.5. Middle East and Africa 8.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.5.3. Market Opportunity Analysis 8.6. Global Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Region, 2018 – 2024 9. North America Cytomegalovirus Infection Treatment Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 9.1. Drug Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 9.1.1. Antiviral drugs 9.1.1.1. Foscarnet 9.1.1.2. Cytovene 9.1.1.3. Vistide 9.1.1.4. Others 9.2. Infection Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 9.2.1. Retinitis 9.2.2. Pneumonia 9.2.3. Gastroenteritis 9.2.4. Others (Mouth Ulcers, Pharyngitis, etc.) 9.3. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Online Pharmacies 9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 9.4.1. US 9.4.2. Canada 9.5. North America Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024 9.6. North America Cytomegalovirus Infection Treatment Market Dynamics – Trends 10. Europe Cytomegalovirus Infection Treatment Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 10.1. Drug Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.1.1. Antiviral drugs 10.1.1.1. Foscarnet 10.1.1.2. Cytovene 10.1.1.3. Vistide 10.1.1.4. Others 10.2. Infection Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.2.1. Retinitis 10.2.2. Pneumonia 10.2.3. Gastroenteritis 10.2.4. Others (Mouth Ulcers, Pharyngitis, etc.) 10.3. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Online Pharmacies 10.4. Country Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 10.4.1. Germany 10.4.2. UK 10.4.3. France 10.4.4. Spain 10.4.5. Italy 10.4.6. Russia 10.4.7. Poland 10.4.8. Rest of Europe 10.5. Europe Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024 10.6. Europe Cytomegalovirus Infection Treatment Market Dynamics – Trends 11. Asia-Pacific Cytomegalovirus Infection Treatment Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 11.1. Drug Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.1.1. Antiviral drugs 11.1.1.1. Foscarnet 11.1.1.2. Cytovene 11.1.1.3. Vistide 11.1.1.4. Others 11.2. Infection Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.2.1. Retinitis 11.2.2. Pneumonia 11.2.3. Gastroenteritis 11.2.4. Others (Mouth Ulcers, Pharyngitis, etc.) 11.3. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies 11.3.3. Online Pharmacies 11.4. Country Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 11.4.1. Japan 11.4.2. China 11.4.3. India 11.4.4. ASEAN 11.4.5. Australia & New Zealand 11.4.6. Rest of Asia-Pacific 11.5. Asia-Pacific Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024 11.6. Asia-Pacific Cytomegalovirus Infection Treatment Market Dynamics – Trends 12. Latin America Cytomegalovirus Infection Treatment Market Analysis, 2012 - 2012 - 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 12.1. Drug Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.1.1. Antiviral drugs 12.1.1.1. Foscarnet 12.1.1.2. Cytovene 12.1.1.3. Vistide 12.1.1.4. Others 12.2. Infection Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.2.1. Retinitis 12.2.2. Pneumonia 12.2.3. Gastroenteritis 12.2.4. Others (Mouth Ulcers, Pharyngitis, etc.) 12.3. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.3.1. Hospital Pharmacies 12.3.2. Retail Pharmacies 12.3.3. Online Pharmacies 12.4. Country Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 12.4.1. Brazil 12.4.2. Mexico 12.4.3. Argentina 12.4.4. Venezuela 12.4.5. Rest of Latin America 12.5. Latin America Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024 12.6. Latin America Cytomegalovirus Infection Treatment Market Dynamics – Trends 13. Middle East and Africa Cytomegalovirus Infection Treatment Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 13.1. Drug Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.1.1. Antiviral drugs 13.1.1.1. Foscarnet 13.1.1.2. Cytovene 13.1.1.3. Vistide 13.1.1.4. Others 13.2. Infection Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.2.1. Retinitis 13.2.2. Pneumonia 13.2.3. Gastroenteritis 13.2.4. Others (Mouth Ulcers, Pharyngitis, etc.) 13.3. Distribution Channel Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.3.1. Hospital Pharmacies 13.3.2. Retail Pharmacies 13.3.3. Online Pharmacies 13.4. Country Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 13.4.1. Gulf Cooperation Council (GCC) Countries 13.4.2. Israel 13.4.3. South Africa 13.4.4. Rest of MEA 13.5. MEA Cytomegalovirus Infection Treatment Market - Opportunity Analysis Index, By Drug Type, By Infection, By Distribution Channel, and Country, 2018 – 2024 13.6. MEA Cytomegalovirus Infection Treatment Market Dynamics – Trends 14. Competition Landscape 14.1. Strategic Dashboard of Top Market Players 14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis) 14.2.1. F. Hoffmann-La Roche AG (Switzerland) 14.2.2. GlaxoSmithKline plc (U.K.) 14.2.3. Merck & Co., Inc. (U.S.) 14.2.4. AiCuris Anti-infective Cures GmbH (Germany) 14.2.5. Vical, Inc. (U.S.) 14.2.6. Chimerix, Inc. (U.S.) 14.2.7. ViroPharma (U.S.) 15. Research Methodology 16. Key Assumptions and Acronyms
  • F. Hoffmann-La Roche AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • Merck & Co., Inc. (U.S.)
  • AiCuris Anti-infective Cures GmbH (Germany)
  • Vical, Inc. (U.S.)
  • Chimerix, Inc. (U.S.)
  • ViroPharma (U.S.)